Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Amgen Inc. is conducting a Phase 1 clinical study titled A Phase 1, Randomized, Double-blind, Placebo-controlled, Integrated Single Ascending Dose, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma. The study aims to assess the safety and tolerability of AMG 691, which could significantly impact asthma treatment approaches.
Intervention/Treatment: The study tests AMG 691, a drug administered via subcutaneous injection, alongside a placebo. It is designed to evaluate the drug’s effects in both healthy individuals and those with mild-to-moderate asthma.
Study Design: This interventional study is randomized and double-blind, meaning neither participants nor investigators know who receives the drug or placebo. The study follows a sequential intervention model with a primary focus on treatment, ensuring a thorough evaluation of AMG 691’s safety and efficacy.
Study Timeline: The study began on October 16, 2024, with ongoing recruitment. The last update was submitted on June 25, 2025. These dates are crucial for tracking the study’s progress and anticipating future developments.
Market Implications: The successful development of AMG 691 could enhance Amgen’s portfolio, potentially boosting its stock performance. Investors should watch for updates as positive results might influence market dynamics, especially in the competitive asthma treatment sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.